Issue of Equity - Conversion of Loan Notes
Trellus Health plc has issued 48,692,603 new Ordinary Shares following the conversion of £50,000 of the principal amount outstanding under the second tranche of Secured Convertible Loan Notes, with admission to trading on AIM expected around April 13, 2026. Following this admission, the Company will have a total of 322,330,221 Ordinary Shares in issue, which will serve as the denominator for shareholders determining notification requirements under FCA rules.
Select text to share a quote on X · sign in to keep highlights & notes in your TRLS notes
LONDON, U.K. AND NEW YORK, U.S. (8 April 2026). Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that further to the Company's announcement on 30 December 2025 and the passing of the relevant resolutions at the General Meeting on 20 January 2026, the Company has issued 48,692,603 new Ordinary Shares following the conversion of £50,000 of the principal amount outstanding under the second tranche of the Secured Convertible Loan Notes.
Accordingly, application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 48,692,603 new Ordinary Shares to trading on AIM will become effective on, or around, 13 April 2026 ("Admission").
Total voting rights
Following admission the Company will have 322,330,221 Ordinary Shares in issue. The Company holds no ordinary shares in treasury. Therefore, the total number of voting rights in the Company is 322,330,221.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.